ライフサイエンスコーパス: nalidixic acid

1 chloramphenicol, but all were susceptible to nalidixic acid.

2 and exhibited intermediate susceptibility to nalidixic acid.

3 ted for strongly by ciprofloxacin but not by nalidixic acid.

4 concentrations of rifampicin, kanamycin, and nalidixic acid.

5 m-sulfamethoxazole; 4 were also resistant to nalidixic acid.

6 pecifically deficient in the SOS response to nalidixic acid.

7 %) demonstrated a MIC > or = 16 microg/mL to nalidixic acid.

8 tment, and which were also hypersensitive to nalidixic acid.

9 om exogenous agents such as UV radiation and nalidixic acid.

10 ve and represent a more specific response to nalidixic acid.

11 e found to be upregulated in the presence of nalidixic acid.

12 lyze indoxyl acetate and their resistance to nalidixic acid.

13 ment of Health were tested for resistance to nalidixic acid.

14 4c was potent as the prototypical quinolone, nalidixic acid (1), with an IC50 value of 58.3 microgram

15 p exhibited low levels of resistance towards nalidixic acid (10%) and tetracycline (8.2%).

16 t antibiotic resistance rates were found for nalidixic acid (15/21; 71.4%), tetracycline (9/21; 42.8%

17 ole (63% of 10,561 isolates, 95% CI: 52-73), nalidixic acid (30% of 9819 isolates, 95% CI: 21-40), ox

18 100%), ceftazidime (100%), meropenem (100%), nalidixic acid (93.1%) and sulfamethoxazole/trimethoprim

19 When nalidixic acid, a DNA synthesis inhibitor, was added to

20 on-inducible lexA mutant hypersusceptible to nalidixic acid, a property restricted to fluoroquinolone

21 occus isolates grown on blood agar, colistin-nalidixic acid agar (CNA), and mannitol salt agar (MSA);

22 B streptococcus, with culture using neomycin-nalidixic acid agar (NNA) and LIM broth.

23 eep blood agar, chocolate agar, and colistin-nalidixic acid agar after 24 to 48 h of incubation at 35

24 d sharply increasing trends in resistance to nalidixic acid and ciprofloxacin for both ST and SPA.

25 n it to be more sensitive to CCCP, PMA, PCP, nalidixic acid and DOC than the parent strain.

26 We identified two drugs, nalidixic acid and dorzolamide, that potently inhibit th

27 xacin), and three quinolones (oxolinic acid, nalidixic acid and flumequine) in eggs is presented.

28 e induced in a LexA-dependent manner by both nalidixic acid and mitomycin C, identifying these as mem

29 on and the addition of the gyrase inhibitors nalidixic acid and novobiocin.

30 emiselective blood agar medium incorporating nalidixic acid and sulfamethazine (NAS) is described.

31 ays a role in modulating the SOS response to nalidixic acid and that the response is more complex tha

32 antibiotics (vancomycin, amphotericin B, and nalidixic acid), and the efficacy of solid (Herrold's eg

33 azole, 312 (28%) to tetracycline, 19 (2%) to nalidixic acid, and 6 (0.5%) to ciprofloxacin.

34 In contrast, addition of rifampin, nalidixic acid, and chloramphenicol had little effect on

35 ant resistant to the prototype of quinolone, nalidixic acid, and created complexes on DNA detected by

36 eased spontaneous resistance to rifampin and nalidixic acid, and MMC/uvrD double mutants exhibited hi

37 g tetracycline, chloramphenicol, ampicillin, nalidixic acid, and rifampin.

38 ns known to be required for SOS induction by nalidixic acid are RecA and RecBC.

39 ion elongation was blocked by hydroxyurea or nalidixic acid, arrested cells contained one partially r

40 antially reduced for SOS induction following nalidixic acid but not UV treatment, and which were also

41 ot hydrolyze hippurate, and was sensitive to nalidixic acid but resistant to cephalothin.

42 DNA-damaging agents, such as mitomycin C and nalidixic acid, caused only limited elongation.

43 r alkaline phosphatase, and was resistant to nalidixic acid, cephalothin, and trimethoprim-sulfametho

44 , the MICs and inhibition zone diameters for nalidixic acid, ciprofloxacin, levofloxacin, and ofloxac

45 molar tooth appearance on anaerobic colistin nalidixic acid (CNA) agar which likely facilitated its d

46 iated to determine whether Columbia colistin-nalidixic acid (CNA) agar would be an equally sensitive,

47 nto blood (blood agar plate [BAP]), colistin-nalidixic acid (CNA), and MacConkey agars in 5% CO2 for

48 Disk diffusion using these antibiotics and nalidixic acid failed to detect some low-level-resistant

49 els of the AcrAB-TolC pump, thereby removing nalidixic acid from the organism.

50 sed to rifampicin (transcription inhibitor), nalidixic acid (gyrase inhibitor), or A22 (MreB-cytoskel

51 r characteristics, (ii) the concentration of nalidixic acid, (iii) the 48 organics identified in the

52 duction and demonstrated that one quinolone (nalidixic acid) improved glucose tolerance in obese mice

53 A subset of SOS genes lost their response to nalidixic acid in the dnaQ mutant strain, while two test

54 usceptible to ciprofloxacin but resistant to nalidixic acid in vitro, a pattern associated with fluor

55 Overall, these results suggest that nalidixic acid-induced DNA breaks are generated either b

56 repair DNA damage via UV-induced DNA damage, nalidixic acid-induced double-strand breaks, and methyl

57 The prototype quinolone, nalidixic acid, kills wild-type Escherichia coli only by

58 culture on MacConkey agar supplemented with nalidixic acid (MACnal) and compared to overnight broth

59 Resistance to nalidixic acid may be useful in the identification of E.

60 rofloxacin (MR = 0.17, 95% CI 0.03-0.97) and nalidixic acid (MR = 0.28, 95% CI 0.15-0.53) for zinc-tr

61 bind not only quinolone antibiotics such as nalidixic acid (NA) and flumequine (FLU), but also salic

62 R), sarafloxacin (SAR), oxolinic acid (OXO), nalidixic acid (NAL) and flumequine (FLU) were separated

63 al distribution of the organism and apparent nalidixic acid (NAL) resistance.

64 ous Fenton-like reactions for the removal of nalidixic acid (NAL), a recalcitrant quinolone antibacte

65 The requirement for DksA in repair of nalidixic acid (Nal)-induced DSBs or for the formation o

66 susceptibility, the proportion resistant to nalidixic acid (NAL-R) increased from 2008 to 2012 (Typh

67 Typhi [MDRST]); 758 (38%) were resistant to nalidixic acid (nalidixic acid-resistant S. Typhi [NARST

68 The combination of neomycin-nalidixic acid (NNA) agar and a selective broth medium (

69 on blood agar medium containing neomycin and nalidixic acid (NNA).

70 were 2.2 [ampicillin (AMP), p=0.017] to 23 [nalidixic acid (NX), p<0.001] times more likely to harbo

71 cs, gentamicin, ceftazidime, nitrofurantoin, nalidixic acid, ofloxacin.

72 howed increased survival on media containing nalidixic acid or rifampicin, but did not have an increa

73 ere uncovered as being uninducible by either nalidixic acid or UV treatment.

74 Nalidixic acid passed undegraded through the MBR and was

75 itt broth supplemented with 10 micrograms of nalidixic acid per ml and 15 micrograms of colistin per

76 The cellular response to nalidixic acid perturbation was analyzed using this form

77 were selected on the basis of resistance to nalidixic acid, representing a variety of the most preva

78 s to rifampicin resistance (RifR) (rpoB) and nalidixic acid resistance (NalR) (gyrA).

79 es of spontaneous mutation to rifampicin and nalidixic acid resistance in one medium and one fast str

80 e efflux contributes to the overall level of nalidixic acid resistance.

81 d an identical pattern on PFGE, and all were nalidixic acid resistant.

82 fraction of kanamycin-resistant (Km(r)) and nalidixic acid-resistant (Nal(r)) isolates showed reduce

83 About 10% of the nalidixic acid-resistant (Nal(r)) mutants in a transposi

84 ompared to 100% of those inoculated with the nalidixic acid-resistant (Nal(r)) parent and 100% of tho

85 triaxone was observed, 20 isolates (7%) were nalidixic acid-resistant (NARST).

86 ations in the gyrA gene were present in most nalidixic acid-resistant isolates.

87 758 (38%) were resistant to nalidixic acid (nalidixic acid-resistant S. Typhi [NARST]) and 734 NARST

88 We found a strong association between nalidixic acid-resistant Salmonella enterica serotype En

89 experiments, detection and enumeration of a nalidixic acid-resistant strain of E. coli O157 in bovin

90 Nalidixic acid-resistant strains harbored mutations in G

91 eptibility to various antibiotics, including nalidixic acid, rifampin, novobiocin, and chloramphenico

92 ty of Todd-Hewitt medium with gentamicin and nalidixic acid (SBM) with our current method of direct p

93 e, such as qnr, is often not detected by the nalidixic acid screen test.

94 re resistant to ampicillin, chloramphenicol, nalidixic acid, streptomycin, sulfisoxazole, tetracyclin

95 Quinolone antibacterial drugs such as nalidixic acid target DNA gyrase in Escherichia coli.

96 protect cells from the quinolone antibiotic nalidixic acid that induces a multidrug efflux pump and

97 Nalidixic acid, the prototype antibacterial quinolone, i

98 perturb a GyrA-GyrA dimer interface allowed nalidixic acid to fragment chromosomes and kill cells in

99 A disk diffusion breakpoint was derived for nalidixic acid to serve as a surrogate marker for gyrase

100 Novobiocin and nalidixic acid treatment both resulted in rapid loss of

101 specifically deficient in SOS induction upon nalidixic acid treatment by using a dinD::lacZ reporter

102 of DNA fragments by GyrA antiserum following nalidixic acid treatment of cells.

103 chromosome replication was blocked by either nalidixic acid treatment or thymine starvation, the tran

104 hed greater than 10-fold in the medium after nalidixic acid treatment, suggesting these were released

105 ically necessary for SOS induction following nalidixic acid treatment.

106 bial mixture of polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin (PANTA) was

107 PANTA reagent (polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin), reconstit

108 several additional SOS genes in response to nalidixic acid using real-time PCR.

109 0 microg of amphotericin B, and 20 microg of nalidixic acid (VAN) per ml.

110 ween high efflux and increased resistance to nalidixic acid was found.

111 The deficient response to nalidixic acid was rescued by the presence of the wild-t

112 rom the production of an antibacterial drug (nalidixic acid) was investigated employing a membrane bi

113 oteins involved in the cytotoxic response to nalidixic acid, we screened for E. coli mutants specific

114 genes not previously known to be induced by nalidixic acid were also reproducibly upregulated.

115 o the selection of the first clinical agent, nalidixic acid, were ever published by the discoverers.

116 he wild, stranded dolphins were sensitive to nalidixic acid, whereas the isolates from the collection